Comprehensive Add on Study in Japan

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 574 participants.

Also called NCT01204294

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 574 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01204294
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01204294. Randomized; no masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2012-01 (actual). Results posted on 2013-01-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comprehensive Add on Study in Japan
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Linagliptin
Intervention (Drug)
Linagliptin
Intervention (Drug)
Metformin
Intervention (Drug)
Metformin
Intervention (Drug)
Linagliptin
Intervention (Drug)
Linagliptin
Intervention (Drug)
Linagliptin
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01204294
Content hash
e59ecfec0e9e40fb633b02bc87308442e6163f4958b37e00620fbda593479e8b